In the analysis of cancer stem cells marker, we found that the combination GSK461364 plus docetaxel decreased the number of CD44+/CD24-/dim in SUM149 (from 26% in DMSO to 18% after treatment, S1 Appendix Fig 1A) and SUM159 (from 89% in DMSO to 77% after treatment, S1 Appendix Fig 1B) compared to control (DMSO). The gene discussed is CD44; the disease is cancer.